Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

Abstract Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that utilize the ubiquitin proteasome system (UPS) to degrade proteins of interest (POI). PROTACs are potentially superior to conventional small molecule inhibitors (SMIs) because of their unique mechanism of ac...

Full description

Bibliographic Details
Main Authors: Yonghan He, Sajid Khan, Zhiguang Huo, Dongwen Lv, Xuan Zhang, Xingui Liu, Yaxia Yuan, Robert Hromas, Mingjiang Xu, Guangrong Zheng, Daohong Zhou
Format: Article
Language:English
Published: BMC 2020-07-01
Series:Journal of Hematology & Oncology
Subjects:
PROTAC
Cell-specific E3 ligases
Small molecule inhibitor
Hematologic malignancy
Online Access:http://link.springer.com/article/10.1186/s13045-020-00924-z

Internet

http://link.springer.com/article/10.1186/s13045-020-00924-z

Similar Items